Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM).~* Are naïve to diabetes injectable therapies and have not used any oral antihyperglycemic medications (OAMs) during the 3 months preceding screening.~* Have HbA1c between ≥7.0% and ≤9.5%.~* Be of stable weight (± 5%) for at least 3 months before screening.~* Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening.~Exclusion Criteria:~* Have type 1 diabetes mellitus.~* Have had chronic or acute pancreatitis any time prior to study entry.~* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment.~* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.~* Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m².~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 10mg of tirzepatide as subcutaneous injection once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 15mg of tirzepatide as subcutaneous injection once a week.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo as subcutaneous injection once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).